Superworth

Caris Life Sciences PE ratio CAI

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Oct 23, 2026
86.5×
Earnings per share, 12 months
$0.37
to Jun 30, 2026
Share price
$32.00
Oct 23, 2026
Peer median
35.9×

Caris Life Sciences' PE ratio is 86.5× as of Oct 23, 2026: a share price of $32.00 against $0.37 of earnings per share over the last twelve months.

It earned $0.37 a share over the twelve months to Jun 30, 2026, against a share price of $32.00 on Oct 23, 2026. It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.

The median for 10 diagnostics and research stocks of a similar size is 35.9×.

Earnings per share over time

A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$11.17n/a
FY2024−$10.67n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.00n/a$0.37
Q1 FY26$0.00n/a−$7.60
Q4 FY25$0.29n/a−$11.17
Q3 FY25$0.08n/a−$13.20
Q2 FY25−$7.97n/a−$15.87
Q1 FY25−$3.57n/a−$10.44
Q4 FY24−$1.74n/a−$10.67
Q3 FY24−$2.59n/an/a
Q2 FY24−$2.54n/an/a
Q1 FY24−$3.80n/an/a

Against its peers

Companies in Medical - Diagnostics & Research nearest Caris Life Sciences' size, closest first, today.

CompanyPE ratio
CAICaris Life Sciences86.5×
BIOBio-Rad Laboratories44.8×
LNTHLantheus24.2×
BLLNBillionToOne166×
RVTYRevvity75.6×
MEDPMedpace39.2×
VCYTVeracyte34.2×
CDNACareDx33.4×
LHLabcorp27.2×
DGXQuest Diagnostics25.7×
MTDMettler-Toledo International37.6×
Peer median35.9×

Where Caris Life Sciences ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Caris Life Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.